蘇州一宸生物醫藥科技有限公司
Suzhou NovaTech Biomedical Co., Ltd.
一宸生物醫藥成立于 2015 年，總部位于江蘇南通市，是一家生物醫藥新技術和新藥物的研發企業。擁有四大國際領先創新藥研發平臺，包括基于原創結構技術和新靶點的。全人源單克隆抗體平臺；雙特異性抗體平臺；超長效融合蛋白平臺； 全新機制抗病毒藥物平臺；研發管線專注于實體腫瘤、自身免疫性疾病和新冠病毒等重大疾病。公司抗新冠病毒感染I類新藥（口服劑）采用全新藥理機制與獨家靶點，屬中國首款，已在海外完成臨床I期試驗，臨床II期試驗準備工作已經開始。該藥物具有高特異性預防并治療新冠病毒感染的獨特雙重能力，有望快速占領國內外新冠治療領域的巨大市場空白。
Founded in 2015 and headquartered in Nantong, China. Yichen Biomedical is a research and development Company. It has four international leading innovative drug research and development platforms.Humanized antibody platform; Bispecific antibody platform; Ultra-long-acting fusion protein platform;New mechanism antiviral drug discovery platform.The R&D pipeline focuses on major diseases such as solid tumors, autoimmune diseases and Coronavirus (COVID-19). The company's new drug against COVID-19 infection has a novel mechanism and unique drug target. It has completed the Phase I clinical trial overseas, and is preparing the Phase II clinical trial. The drug has the unique dual effects in preventing and treating COVID-19 infection, and is expected to hit the huge global market quickly.
